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The injured adult mammalian central ner-
vous system (CNS) lacks the ability for 
axon regeneration,[1,2] predominantly due 
to specific inhibitors expressed on residual 
myelin and on astrocytes recruited to the 
site of injury.[3–7] Several inhibitor proteins 
have been identified, one of them being the 
myelin-associated glycoprotein (MAG).[8] 
MAG is a transmembrane glycoprotein[9] 
belonging to the so-called Siglecs, a family 
of the sialic acid-binding immunoglobulin 
like lectins.[10,11] On the surface of neurons, 
MAG interacts with two classes of targets: 
Proteins of the family of Nogo receptors 
(NgR)[12,13] and brain gangliosides (GD1a 
and GT1b)[11,14–16] (Fig. 1). Although the 
relative roles of gangliosides and NgRs as 
MAG ligands have yet to be resolved,[8,17] 
in some systems, MAG inhibition is com-
pletely reversed by sialidase treatment, sug-
gesting that MAG uses sialylated glycans 
as its major axonal ligands.[18] Therefore, 
blocking MAG with potent glycomimetic 
antagonists may be a valuable therapeutic 
approach to enhance axon regeneration.
Schnaar and coworkers[19] reported that 
a limited set of structurally related ganglio-
sides like GT1b or GQ1bα (Fig. 2), known 
to be expressed on myelinated neurons in 
vivo, are functional ligands for MAG. Re-
cently, the MAG-affinity of a partial struc-
ture of GQ1bα, the tetrasaccharide 2, could 
clearly be correlated with its ability to re-
verse MAG-mediated inhibition of axonal 
outgrowth.[22] Since SAR studies indicate 
that not only the terminal, α(2-3)-linked, 
but also the internal, α(2-6)-linked sialic 
acid is essential for MAG binding, various 
partial structures of 1[20] as well as sulfated 
analogs, e.g. 3[21] were synthesized.
Design of Glycomimetics
High-affinity MAG antagonists with 
concurrent drug-like pharmacokinetic 
properties would provide a valuable tool 
for the investigation of the exact physio-
logical role of MAG in the inhibitory 
cascade leading to the collapse of growth 
cones, the reason for the failure of regener-
ation of injuries in the CNS. Because of the 
shallow binding site typically present in 
lectins, carbohydrate ligands often exhibit 
only modest, i.e. milli- to micromolar af-
finities.[23] This also proved true for MAG 
with a 180 micromolar affinity for tetrasac-
charide 4, the binding epitope of GQ1bα 
(Fig. 3).[24] In addition to the therefore 
required improvement of affinity, phar-
macokinetic issues as metabolic stability, 
e.g. sialidase stability[26] or permeation of 
the blood brain barrier have also to be ad-
dressed. For the in vivo application, it is 
planned to add the antagonist by infusion 
to the site of injury. Therefore, a prolonged 
stability in the cerebrospinal fluid is also 
required. Furthermore, to maintain the 
necessary minimal therapeutic concentra-
tion in the CNS, a loss of the antagonist by 
an active or passive transport mechanism 
would be detrimental.
In a first approach, we focused on a 
reduction of the structural complexity 
of GQ1bα (1) and, at the same time, an 
improvement of pharmacodynamic and 
pharmacokinetic properties. From vari-
ous structure-affinity relationship stu dies 
(SAR),[27,28] the tetrasaccharide 4 was 
identified as the minimal carbohydrate 
epitope. Detailed binding information 
of epitope 4 was obtained by STD NMR 
experiments[24] (Fig. 3). They indicated 
important lipophilic interactions of the 
glycerol side chain of the α(2-3)-linked 
N-acetyl neuraminic acid (Neu5Ac), the 
b-face of the galactose moiety and the N-
acetates of both Neu5Ac residues. In addi-
tion, the carboxylates of the two Neu5Ac 
moieties are involved in salt bridges and 
the C(9)-OH of the α(2-3)-linked Neu5Ac 
is forming a relevant hydrogen bond.[25] A 
verification of these findings by docking 
studies to a homology model of MAG[29,30] 
revealed the corresponding amino acids 
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forming the binding site (Figs 3 and 6). 
Based on this information, a rational ap-
proach for the design of MAG antagonists 
was envisaged.
Replacement of the  
Galb(1-3)GalNAc Core
In a first approach, the Galb(1-3)
GalNAc core, establishing a lipophilic 
contact with MAG,[24] was replaced by 
biphenyl (5), which acts as a linker 
to position the carboxylates of the two 
Neu5Ac moieties in the appropriate spa-
tial orientation (Fig. 4). In addition, the 
biphenyl linker enables a lipophilic con-
tact with the binding site and at the same 
time reduces the high polarity of the lead 
structure 4. Starting from glycosyl donor 
6,[37] the building blocks 7 and 8 were 
synthesized, permitting the formation of 
the protected test compound 9 by Suzuki 
coupling in an excellent yield (Scheme 1). 
Mimic 5 was obtained after deprotection 
under Zemplén conditions and showed a 
four-fold reduction of affinity compared 
to tetrasaccharide 4[36] (Table 1). For an 
additional structural simplification, the 
α(2-6)-linked Neu5Ac moiety was re-
placed by acetic acid leading to antagonist 
10, which showed a slightly lower affin-
ity than 5. To further fine-tune the spatial 
orientation of the carboxylates, the biphe-
nyl linker was replaced by a 1,2,3-triazol-
4-yl-phenyl moiety, a modification with 
practically no influence on the affinity for 
MAG.[38]
Lipophilic Substituents on the  
α(2-3)-linked Sialic Acid
A pivotal simplification of the tetrasac-
charide lead structure 4 was reported by 
Kelm and Brossmer who modified the α(2-
3)-linked sialic acid in the 2-, 5- or 9-posi-
tion to obtain up to a ten-fold enhancement 
of affinity compared to lead 4.[28,39,40] Fur-
ther optimization of these three positions 
led to antagonist 17 (Scheme 2) with a 
360-fold improved affinity, i.e. 500 nano-
molar.[25,41]
Starting from the Boc-protected neur-
aminic acid derivative 12,[41] 14 was ob-
tained by deprotection with TMSCl and 
PhOH (13) followed by acylation with 
fluoroacetyl chloride. Glycosylation using 
2,3-difluorobenzyl alcohol (15), ami-
dation using modified Staudinger condi-
tions[42] (16) and final deprotection gave 

































































































































From ChemiCal researCh to industrial appliCations CHIMIA2010,64,No.1/2 19
For the KD determination in the Bi-
acore assay, MAGd1-3-Fc could not be im-
mobilized by amine coupling, because 
three lysines are positioned in proximity 
to the carbohydrate binding site (Fig. 5B). 
Therefore, MAGd1-3-Fc was immobilized 
on a dextran chip containing a surface of 
covalently bound protein A. A reference 
cell providing only protein A was used to 
compensate unspecific binding to the ma-
trix (Figs 5C and 5D).
Stability in Cerebrospinal Fluid
For nerve regeneration, MAG antago-
nists will most likely be applied to the CNS 
by a local infusion. We therefore tested the 
stability of the fluoroacetate 17 in artifi-
cial cerebrospinal fluid (aCSF)[44] for 19 h 
at 37 °C and, as a control, in buffer solu-
tion. According to LC-MS analysis, more 
than 95% of the initial concentrations of 
17 were recovered from both media, pre-
dicting a high stability in the CNS, the 
Lipophilic and Hydrophilic 
Replacements of the α(2-6)-linked 
Sialic Acid
Since the carboxylate of the α(2-6)-
linked Neu5Ac in tetrasaccharide 4 forms 
a salt bridge with Lys67 and the N-acetate 
a lipophilic contact with Tyr69 (Figs 3 and 
6A), hydrophilic as well as lipophilic sub-
stitutes were explored. A replacement by 
lactic acid (22) or biphenylmethyl (23) 
yielded affinities in the range of tetrasaccha-
ride 4 (Scheme 3). Combined with the most 
successful modification of the 9-position 
of the α(2-3)-linked Neu5Ac (Scheme 2) 
antagonist 29 with low micromolar affinity 
could be identified (Scheme 4).[30]
Biological Evaluation
Determination of Affinity for MAG
For the evaluation of the binding prop-
erties of these new MAG antagonists two 
assay formats were applied; a fluorescent 
hapten binding assay[43] and a surface 
plasmon resonance based biosensor (Bi-
acore) experiment[30,41] (Fig. 5). For the 
hapten inhibition assay, a recombinant 
protein consisting of the three N-terminal 
domains of MAG and the Fc part of hu-
man IgG (MAGd1-3-Fc) was produced by 
expression in CHO cells and affinity puri-
fication on protein A-agarose[43] (Fig. 5A). 
The relative inhibitory concentrations 
(rIC50) of the test compounds as competi-
tive ligands were determined in microti-
ter plates coated with fetuin as binding 
target for MAGd1-3-Fc. By complexing 
the Fc-part with alkaline phosphatase-
labeled anti-Fc antibodies and measuring 
the initial velocity of fluorescein release 
from fluorescein diphosphate, the amount 
of bound MAGd1-3-Fc can be determined. 
The affinities were measured relative to 







































































































































































































































arIC50 is the concentration when 50% of the protein are inhibited, measured relative to reference compound 4;














































































































































































26 (R = H)














12[41], R = Boc































































From ChemiCal researCh to industrial appliCations CHIMIA2010,64,No.1/2 21
target compartment of an in vivo applica-
tion. Furthermore, the logD
octanol/water value 
of –0.26 is beneficial for an intrathecal ap-
plication, since this distribution coefficient 
suggests a loss from the CNS compartment 
by a passive transport mechanism to be un-
likely. This hypothesis is further supported 
by the results of the BBB-PAMPA assay 
showing a log P
e
 value of –10 for 17. For 
values below –5.7, no passive permeation 
through the BBB is expected.[45]
Docking of Antagonists to a 
Homology Model of MAG
For docking studies of the antagonists 
4, 17 and 29, a homology model of MAG 
based on the three-dimensional structure 
of sialoadhesin was used.[29,30] The ligands 
were first manually docked to the binding 
pocket of the MAG model using the salt 
bridge to Arg118 and the hydrogen bond 
of the 9-OH to the backbone carbonyl of 
Phe129 as anchor points. Next, the pro-
tein–ligand complex was minimized in 
aqueous solution and then subjected to a 
molecular-dynamics equilibration proto-
col. The lowest-energy binding modes of 
tetrasaccharide 4 and mimics 17 and 29 are 
compared in Fig. 6. 
All three antagonists, tetrasaccharide 4 
(Fig. 6A) and the mimics 17 (Fig. 6B) and 
29 (Fig. 6C) form salt bridges with Arg118. 
In addition, the three antagonists establish 
a crucial hydrophobic interaction between 
the 5-amido groups and the side chains of 
Trp22 and Tyr124. Whereas 4 develops a 
second salt bridge between the carboxylate 
of the α(2-6)-linked Neu5Ac and Lys67, 
the mimics 17 and 29 establish prominent 
interactions with two hydrophobic pock-
ets. Glu131 and Tyr127 are homing the p-
chloro benzamide substituent and the side 
chains of Trp59, Tyr60, Tyr69 and Tyr116 
are lining the main hydrophobic pocket 
and accommodate the 2,3-difluorobenzene 
(17) and biphenylmethyl moiety (29), 
respectively. 
Conclusion
Overall, with antagonist 17 the affin-
ity of lead 4 could be improved more than 
350-fold. Its pharmacokinetic properties 
certify the drug-like properties of the best 
so far identified MAG antagonist. A fur-
ther important issue to be addressed is 
the metabolic stability of the presented 
oligosaccharide mimics. In general, the 
substrate specificity of mammalian siali-
dases is determined by the linkage type of 
the terminal sialic acid residue (2-3, 2-6 
or 2-8) and does not depend on the struc-
ture of the underlying oligosaccharide.[46] 
Therefore, it cannot be excluded that 
the presented mimics are metabolically 
cleaved by sialidases. Nevertheless, this 
new class of MAG blockers constitute an 
important step toward the development of 
potent oligosaccharide mimics. 
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Fig.6.Thethree-dimensionalstructuresof4,17and29weregenerated
usingtheMacroModelsoftware[31]andoptimizedinaqueoussolutionby
meansoftheAMBER*forcefield.[32]Atomicpartialcharges(MNDO/ESP)
werethengeneratedusingMOPAC.[33]Theligandswerefirstmanually
dockedandtheprotein–ligandcomplexwasminimizedinaqueous
solutionandthensubjectedtoamolecular-dynamicsequilibration
protocol(24psat10K,heatingto300Kduring48ps,1ps=10–12
s),followedbyamoleculardynamicat300Kfor4nsperformedwith
Desmond[34](at2.4psintervals).Thestructuresofthetrajectoryalong
themoleculardynamicsimulationhavebeensampledthrougha
hierarchicalclusterlinkagemethodat2.4psintervals.Theimageshave
beengeneratedusingVMD.[35]A)Tetrasaccharide4,asubstructureof
gangliosideGQ1bα,B)antagonist29;antagonist17.
